NRx develops life-saving treatments to Bring Hope to Life. Read the latest news about our company, medicines, and pipeline.

NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant

RADNOR, Pa., Jan. 27, 2022 /PRNewswire/ — NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective […]

NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge

A Southwestern hospital has reported safety data collected under the Federal Right to Try law indicating that 16 of 19 patients (84%) with COVID-19 respiratory failure treated with ZYESAMI® by […]